Pfizer Inc and Nektar Therapeutics said clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.Over the course of the clinical trials, Pfizer said six of the 4,740 Exubera-treated patients versus one of the 4,292 patients not treated with Exubera developed lung cancer.
It updated the Exubera labeling to include a warning with safety information about lung cancer cases found in patients who used Exubera.
Pfizer said in October it would stop marketing Exubera, which was a commercial flop. The warning in the label stemmed from an ongoing review of data from the Exubera clinical trial program and post-marketing experience by Pfizer and the U.S. Food and Drug Administration, Pfizer said. (Reuters)